4.8 Article

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients

期刊

JOURNAL OF HEPATOLOGY
卷 53, 期 3, 页码 439-443

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2010.03.022

关键词

IL28; SNP; Histological activity; Inflammation; gamma-GTP

资金

  1. Ministry of Health, Labor, and Welfare, Government of Japan
  2. Ministry of Education Culture Sports Science and Technology, Government of Japan

向作者/读者索取更多资源

Background & Aims: A common genetic variation at the IL28 locus has been found to affect the response of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection. An allele associated with a favorable response (rs8099917 T), which is the major allele in the majority of Asian, American, and European populations, has also been found to be associated with spontaneous eradication of the virus. Methods: As no studies have yet analyzed the effect of the polymorphism on biochemical and inflammatory changes in chronic infection, we analyzed a cohort of patients with chronic hepatitis C (n = 364) for the effect of the IL28 polymorphism on viral, biochemical, and histological findings. Results: We found that the proportion of HCV wild type core amino acids 70 and 91 was significantly greater (p = 1.21 x 10(-4) and 0.034) and levels of gamma-GTP significantly lower (p = 0.001) in patients homozygous for the IL28 major allele. We also found that inflammation activity and fibrosis of the liver were significantly more severe in patients homozygous for the IL28 major allele (p = 0.025 and 0.036, respectively). Although the higher gamma-GTP levels were also associated with higher inflammatory activity and fibrosis, multivariate analysis showed that only the IL28 allele polymorphism, sex, alcohol consumption, and liver fibrosis were independently associated with gamma-GTP levels (p = 0.001, 0.0003, 0.0013, and 0.0348, respectively). Conclusions: These results suggest that different cytokine profiles induced by the IL28 polymorphism resulted in different biochemical and inflammatory conditions during chronic HCV infection and contribute to the progression of liver diseases. (C) 2010 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Surgery

Risk Factors for Hepatocellular Carcinoma After Splenectomy in Liver Cirrhotic Patients

Naruhiko Honmyo, Tsuyoshi Kobayashi, Shintaro Kuroda, Kentaro Ide, Masahiro Ohira, Hiroyuki Tahara, Hiroshi Morimoto, Naoki Tanimine, Michinori Hamaoka, Megumi Yamaguchi, Masateru Yamamoto, Daisuke Takei, Hiroshi Aikata, Kazuaki Chayama, Hideki Ohdan

Summary: This study identified risk factors for hepatocellular carcinoma (HCC) development after splenectomy for portal hypertension. The etiology of cirrhosis, presence of HCC history, and preoperative hemoglobin level were found to be associated with HCC development. The predictive model constructed in this study may assist in surveillance for HCC after splenectomy in patients with portal hypertension.

AMERICAN SURGEON (2023)

Review Gastroenterology & Hepatology

Road to elimination of HCV: Clinical challenges in HCV management

C. Nelson Hayes, Michio Imamura, Junko Tanaka, Kazuaki Chayama

Summary: Since its discovery in 1989, the road to a cure for hepatitis C virus (HCV) has been slow, but most patients can now expect to achieve a sustained virological response (SVR). Adverse events are rare or mild, and patients with compensated cirrhosis and other co-morbidities are often eligible for treatment. However, a small number of patients fail to eradicate the virus even after retreatment.

LIVER INTERNATIONAL (2022)

Article Immunology

Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL

Yosuke Suehiro, Masataka Tsuge, Mio Kurihara, Takuro Uchida, Hatsue Fujino, Atsushi Ono, Masami Yamauchi, Grace Naswa Makokha, Takashi Nakahara, Eisuke Murakami, Hiromi Abe-Chayama, Tomokazu Kawaoka, Daiki Miki, Michio Imamura, Hiroshi Aikata, C. Nelson Hayes, Takashi Fujita, Kazuaki Chayama

Summary: HBV infection upregulates TRAIL-R3, which inhibits both TRAIL-dependent apoptosis and suppression of HBV replication. The upregulation of TRAIL-R3 is regulated by the TRAIL-R3 promoter and HBV signal pathway. The results suggest a mechanism by which HBV persists by escaping host immunity through upregulation of TRAIL-R3.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Gastroenterology & Hepatology

Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study

Osamu Yoshida, Sheikh Mohammad Fazle Akbar, Yusuke Imai, Takahiro Sanada, Kyoko Tsukiyama-Kohara, Takashi Miyazaki, Taizou Kamishita, Teruki Miyake, Yoshio Tokumoto, Hayato Hikita, Masataka Tsuge, Masahito Shimizu, Mamun Al Mahtab, Julio Cesar Aguilar, Gerardo Guillen, Michinori Kohara, Yoichi Hiasa

Summary: This study investigated the safety and efficacy of CVP-NASVAC in treating patients with chronic hepatitis B (CHB). The results showed that CVP-NASVAC induced anti-HBs antibodies and reduced HBsAg levels in some patients, leading to functional cure in 9.5% of the participants.

HEPATOLOGY RESEARCH (2023)

Editorial Material Gastroenterology & Hepatology

Factors for the recurrence of hepatocellular carcinoma after hepatic resection

Masataka Tsuge, Tomokazu Kawaoka, Shiro Oka

JOURNAL OF GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Acute liver injury in a non-alcoholic fatty liver disease patient with chloroform exposure: a case report

Yosuke Suehiro, Takuro Uchida, Masataka Tsuge, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Michio Imamura, Hiroshi Aikata, Koji Arihiro, Shiro Oka

Summary: We present the case of a rare occurrence of acute liver injury in a patient with non-alcoholic fatty liver disease (NAFLD) due to daily exposure to small amounts of chloroform. The patient had been regularly monitored and showed stable alanine aminotransferase (ALT) levels until a sudden increase in late August 2014. The liver injury was attributed to chloroform exposure and was successfully treated with the administration of 600 mg/day of ursodeoxycholic acid.

CLINICAL JOURNAL OF GASTROENTEROLOGY (2023)

Correction Gastroenterology & Hepatology

Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure (Apr, 10.1007/s12072-023-10532-x, 2023)

Serami Murakami, Michio Imamura, Takuro Uchida, Yosuke Suehiro, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Yuji Teraoka, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Nelson C. Hayes, Masataka Tsuge, Hiroshi Aikata, Masahiro Ohira, Hideki Ohdan, Shiro Oka

HEPATOLOGY INTERNATIONAL (2023)

Article Gastroenterology & Hepatology

Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure

Serami Murakami, Michio Imamura, Takuro Uchida, Yosuke Suehiro, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Yuji Teraoka, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Masami Okamoto Yamauchi, Tomokazu Kawaoka, Daiki Miki, Nelson C. Hayes, Masataka Tsuge, Hiroshi Aikata, Masahiro Ohira, Hideki Ohdan, Shiro Oka

Summary: This study evaluated the prognosis and prognostic factors of patients with alcohol-related acute-on-chronic liver failure (ACLF). The cumulative survival rates of patients treated without liver transplantation were 69%, 48%, 41%, and 36% at 1, 3, 6, and 12 months, respectively. Serum IL-6 level and Day-4 MELD score were identified as prognostic factors for mortality within 6 months. Early liver transplantation may be a potential treatment option for patients with poor prognosis.

HEPATOLOGY INTERNATIONAL (2023)

Article Oncology

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

Takahiro Kinami, Kei Amioka, Tomokazu Kawaoka, Shinsuke Uchikawa, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kensuke Naruto, Yuwa Ando, Kenji Yamaoka, Yasutoshi Fujii, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, Shiro Oka

Summary: This study investigated the relationship between radiological response and prognosis in HCC patients to determine whether to continue Atezo + Beva treatment. The results showed that a decrease in AFP level may reflect early efficacy and AFP trends can help decide the treatment strategy. It was found that a 25% or greater increase in AFP value was associated with disease progression and a decrease in AFP was related to improved progression-free survival.

CANCERS (2023)

Article Gastroenterology & Hepatology

Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study

Yusuke Johira, Takashi Nakahara, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, C. Nelson Hayes, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, Shiro Oka

Summary: This study investigated the clinical characteristics of MAFLD-HCC patients compared with NAFLD-HCC patients and considered the validity and challenges of the new criteria. The majority of non-B, non-C HCC cases with hepatic steatosis were attributed to MAFLD. Further examination and revision of the criteria are needed to select fatty liver patients at high risk of developing HCC efficiently.

BMC GASTROENTEROLOGY (2023)

Article Oncology

Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment

Yosuke Tamura, Atsushi Ono, Hikaru Nakahara, Clair Nelson Hayes, Yasutoshi Fujii, Peiyi Zhang, Masami Yamauchi, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Masahiro Serikawa, Daiki Miki, Tomokazu Kawaoka, Wataru Okamoto, Michio Imamura, Yuko Nakamura, Kazuo Awai, Tsuyoshi Kobayashi, Hideki Ohdan, Masashi Fujita, Hidewaki Nakagawa, Kazuaki Chayama, Hiroshi Aikata, Shiro Oka

Summary: High-intensity Gd-EOB-DTPA-enhanced MRI imaging (EOB-MRI) in the hepatobiliary phase (HB) can predict the immune microenvironment and molecular subtype in hepatocellular carcinoma (HCC) patients but not the response to atezolizumab + bevacizumab therapy. The high-intensity group benefits from bevacizumab, while the low-intensity group benefits from atezolizumab.

CANCERS (2023)

Article Oncology

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Shigeki Yano, Tomokazu Kawaoka, Shintaro Yamasaki, Yusuke Johira, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Kei Amioka, Kensuke Naruto, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Masataka Tsuge, Yuji Teraoka, Hirotaka Kouno, Shintaro Takaki, Nami Mori, Keiji Tsuji, Shiro Oka

Summary: A total of 137 HCC patients treated with atezolizumab plus bevacizumab were enrolled in this study. The results showed that lenvatinib is an effective treatment option, as it can prolong the overall survival and progression-free survival of patients. Adverse events were relatively common, but none directly caused death.

CANCERS (2023)

Meeting Abstract Gastroenterology & Hepatology

THE IMPORTANCE OF BODY COMPOSITION MEASUREMENTS DURING LENVATINIB TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

Kenji Yamaoka, Tomokazu Kawaoka, Masanari Kosaka, Yusuke Johira, Yuki Shirane, Ryoichi Miura, Shigeki Yano, Serami Murakami, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Shinsuke Uchikawa, Kenichiro Kodama, Takuro Uchida, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Michio Imamura, Kazuaki Chayama, Hiroshi Aikata

HEPATOLOGY (2022)

暂无数据